Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG 404 + Tarlatamab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG 404 | AMG404|AMG-404|zeluvalimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | AMG 404 is a monoclonal antibody that binds to and inhibits PD-1 signaling, potentially resulting in restoration of anti-tumor immune response (NCI Drug Dictionary). | |
Tarlatamab | Imdelltra | AMG 757|AMG757|AMG-757|tarlatamab-dlle | CD3 Antibody 99 DLL3 Antibody 6 | Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04885998 | Phase I | AMG 404 + Tarlatamab | AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) | Completed | USA | BEL | AUT | 3 |